We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Product News   Apr 28, 2017 | Original story from Cambridge Epigenetix

 
Cambridge Epigenetix Licenses Fundamental DNA Methylation IP from Boston Children’s Hospital

Anjana Rao. Credit: Cambridge Epigenetix

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

InterVenn Enters into Collaboration With Agilent Technologies

Product News

InterVenn, a San Francisco based biotechnology has announced a collaboration with Agilent Technologies. The signing of the collaboration took place on 7 September 2020, with Mr. Fadzhairi Jabar, InterVenn Malaysia’s General Manager, and Mr. Soh Lam Seng, Agilent’s Malaysia Country Manager, Laboratory Solutions Sales.

READ MORE

Biopharma Receives Positive EMA Opinion on Orphan Designation for Pancreatic Cancer Treatment

Product News

Prestige BioPharma Ltd. (hereinafter “Prestige BioPharma”) today announced that the European Medicines Agency (EMA) Orphan Drug Commission (COMP) has granted a positive opinion for an Orphan Drug Designation (ODD) status to its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.

READ MORE

Mogrify Introduces EpiMOGRIFY To Identify Epigenetic Switches

Product News

Mogrify Limited (Mogrify®) today announced the introduction of EpiMOGRIFY. The platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Diagnostics Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE